Applicability of electronic medical record-based clinical research in terms of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

There has been a rapid increase in the use of the electronic medical record (EMR) system. In the present review, we evaluated the applicability of EMR data in terms of the efficacy of various 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) that are currently available. EMR systems will become more valuable for easily accessing, collecting, verifying, and analyzing data. Therefore, an EMR-based clinical pilot study can be conducted quickly prior to performing a large-scale randomized controlled trial (RCT), and it can focus the clinical research before an RCT is performed. Although there are still many limitations in EMR-based clinical research, new information will be available after a large amount of data is collected in the future. EMR data can save time and labor compared with conventional clinical study data, and this is the most important advantage of conventional long-term studies; thus, these data will be advantageous to clinical researchers.